Literature DB >> 30068450

Multimorbidity in Māori and Pacific patients: cross-sectional study in a Dunedin general practice.

Tim Stokes1, Mayur Azam2, Fiona Doolan Noble1.   

Abstract

INTRODUCTION Multimorbidity is a major issue in primary health care. AIM To determine the prevalence of multimorbidity and polypharmacy in one general practice in relation to age, sex and socioeconomic deprivation in Māori and Pacific patients. METHODS A cross-sectional study using data manually extracted from electronic medical records was conducted using a stratified random sample of Māori and Pacific patients aged ≥ 35 years who were enrolled with a large urban Dunedin general practice. The data were analysed to identify the number and type of morbidities, and prevalence of multimorbidity and polypharmacy in relation to age, sex and socioeconomic deprivation. RESULTS Half (52.5% [95% CI 44.5-60.4]) of Māori and 64.3% (95% CI 51.9-75.4) of Pacific patients had multimorbidity; 22.8% (95% CI 16.6-30.1) of Māori and 10.0% (95% CI 4.1-19.5) of Pacific patients had physical and mental health co-morbidity. Fewer (13.6% [95% CI 8.7-19.8]) Māori than Pacific patients (32.9% [95% CI 22.1-45.1]) had polypharmacy. The prevalence of multimorbidity in both Māori and Pacific patients increased with age and with increasing levels of socioeconomic deprivation. The eight most prevalent chronic conditions in both Māori and Pacific patients were obesity, anxiety or depression, hypertension, asthma or chronic obstructive pulmonary disease, gout, diabetes, cardiovascular disease and osteoarthritis. CONCLUSION The high prevalence of multimorbidity in Māori and Pacific patients requires the New Zealand health system to deliver culturally competent primary health care and to re-orientate health-care delivery around multimorbidity.

Entities:  

Mesh:

Year:  2018        PMID: 30068450     DOI: 10.1071/HC17046

Source DB:  PubMed          Journal:  J Prim Health Care        ISSN: 1172-6156


  7 in total

1.  Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity.

Authors:  Mukund Kumar; Natalie Manley; Ted R Mikuls
Journal:  Drugs Aging       Date:  2021-06-09       Impact factor: 3.923

2.  Medication risk management and health equity in New Zealand general practice: a retrospective cross-sectional study.

Authors:  Sharon Leitch; Jiaxu Zeng; Alesha Smith; Tim Stokes
Journal:  Int J Equity Health       Date:  2021-05-11

3.  Protocol for a randomised controlled trial to evaluate the effectiveness of the diabetes community exercise and education programme (DCEP) for long-term management of diabetes.

Authors:  Leigh Hale; Tim Stokes; Bonnie Scarth; Ramakrishnan Mani; Trudy Sullivan; Fiona Doolan-Noble; Prasath Jayakaran; Andrew R Gray; Jim Mann; Christopher Higgs
Journal:  BMJ Open       Date:  2019-02-21       Impact factor: 2.692

4.  The views of New Zealand general practitioners and patients on a proposed risk assessment and communication tool: a qualitative study using Normalisation Process Theory.

Authors:  Sharon Leitch; Alesha Smith; Sue Crengle; Tim Stokes
Journal:  Implement Sci Commun       Date:  2021-02-10

Review 5.  Theoretical explanations for socioeconomic inequalities in multimorbidity: a scoping review.

Authors:  Ludmila Fleitas Alfonzo; Tania King; Emily You; Diana Contreras-Suarez; Syafiqah Zulkelfi; Ankur Singh
Journal:  BMJ Open       Date:  2022-02-23       Impact factor: 2.692

6.  The diabetes community exercise programme plus usual care versus usual care in patients with type 2 diabetes: A randomised, two-arm, parallel, open-label trial.

Authors:  L Hale; C Higgs; A R Gray; J Mann; R Mani; T Sullivan; J Terry; D Keen; T Stokes
Journal:  EClinicalMedicine       Date:  2022-03-25

Review 7.  Household and area-level social determinants of multimorbidity: a systematic review.

Authors:  Elizabeth Ingram; Sarah Ledden; Sarah Beardon; Manuel Gomes; Sue Hogarth; Helen McDonald; David P Osborn; Jessica Sheringham
Journal:  J Epidemiol Community Health       Date:  2020-11-06       Impact factor: 3.710

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.